Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Analgesics

Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab

Michele B. Kaufman, PharmD, BCGP  |  October 9, 2018

After meeting with the FDA, the makers of intravenous meloxicam plan to resubmit the treatment’s new drug application…

FDA Expands Safety Measures for Immediate Release Opioids

Michele B. Kaufman, PharmD, BCGP  |  October 2, 2018

The FDA has expanded the new Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) to include immediate release opioids. The program, which also includes extended release and long acting opioids, will provide education to prescribers and healthcare professionals…

The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials

Michele B. Kaufman, PharmD, BCGP  |  September 6, 2018

The FDA has not approved extended release Remoxy, a gel capsule formulation of oxycodone, concluding that its potential benefits do not outweigh its risks…

EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray

Michele B. Kaufman, PharmD, BCGP  |  August 8, 2018

In late July, the European Commission granted marketing approval for Hyrimoz, which is biosimilar to adalimumab…

A Comprehensive Review of NSAID Cardiovascular Toxicity

A Comprehensive Review of NSAID Cardiovascular Toxicity

Deepan S. Dalal, MD, MPH, Maureen Dubreuil, MD, MS, & David T. Felson, MD, MPH  |  July 18, 2018

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  July 9, 2018

The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…

IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

Michele B. Kaufman, PharmD, BCGP  |  July 2, 2018

In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…

Nonopioid Medication May Be as Effective as Opioids for Chronic Pain

Lara C. Pullen, PhD  |  April 16, 2018

A recent study compared the efficacy of opioids with nonopioid pain treatments in patients with chronic back pain and hip or knee osteoarthritis. After 12 months, researchers found that treatment with opioids was not superior to treatment with nonopioid medication, with only minor differences in patients’ functional responses to the medications…

FDA to Review Abuse Deterrent Oxycodone Capsule & More

Michele B. Kaufman, PharmD, BCGP  |  April 11, 2018

The FDA will discuss a New Drug Application for Remoxy ER during an upcoming advisory committee meeting and recently approved tildrakizumab-asmn to treat adults with plaque psoriasis…

Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

Michele B. Kaufman, PharmD, BCGP  |  April 2, 2018

A recent study examined how often patients exceed the dosing limits of nonsteroidal anti-inflammatory drugs and identified the characteristics of the patients most likely to exceed recommended doses…

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 15
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences